CORDIS · 853995 · H2020
ImmUniverse Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
Coordinator: UNIVERSITA HUMANITAS (IT)
Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle th…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
Co-funding: the European Union contributes €15.5M toward a total project budget of €31.1M — a funding rate of 50%, with the remainder covered by the consortium partners. The project runs over approximately 6.5 years from 2020-01-01 to 2026-06-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from IT
see all →- THCS — European Partnership on Transforming Health and Care Systems101095654 · HORIZON · €91.6M
- c4c — conect4children (COllaborative Network for European Clinical Trials For Children)777389 · H2020 · €67.0M
- ADITEC — Advanced Immunization Technologies280873 · FP7 · €30.0M
- ARCHETYPE SW550 — Demonstration of innovating parabolic solar trough using an alternative heat transfer fluid producing electricity and fresh water: ARChimede Hot Energy TYPology Enhanced Water Solar 550268181 · FP7 · €29.7M
- EPOS IP — EPOS Implementation Phase676564 · H2020 · €18.4M
- COMETHA — 80,000 TON/Y PRECOMMERCIAL INDUSTRIAL SCALE DEMONSTRATION PLANT ON SECOND GENERATION LIGNOCELLULOSIC ETHANOL322406 · FP7 · €17.9M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €15.5M toward a total project budget of €31.1M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-JTI-IMI2-2018-15-two-stage.
- Who coordinates the project?
- The project is coordinated by UNIVERSITA HUMANITAS (IT).
- What is the project timeline?
- The project runs from 2020-01-01 to 2026-06-30 — approximately 6.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 853995.